RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors
Synopsis
Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.
Relmada Therapeutics Inc. (RLMD) shares soared more than 66% in Monday’s pre-market trade after the company announced an update in the Phase 2 trial of its bladder cancer treatment.
Relmada stated that NDV-01 demonstrated a durable 76% complete response (CR) rate at 12 months, with a 95% CR rate at any time in high-risk non-muscle-invasive bladder cancer.
Retail sentiment on Stocktwits around Relmada Therapeutics was trending in the ‘bullish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.